Phase 1 Open-Label, Multicenter Study of First-in-Class RORγ Agonist LYC-55716 (Cintirorgon): Safety, Tolerability, and Preliminary Evidence of Antitumor Activity

Overview of attention for article published in Clinical Cancer Research, June 2019

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (55th percentile)
Average Attention Score compared to outputs of the same age and source

So far, Altmetric has seen 12 X posts from 9 X users, with an upper bound of 59,607 followers.

RT @CCR_AACR: Phase I trial: RORγ agonist LYC-55716 in adults with relapsed/refractory metastatic cancer. https://t.co/frFxMaOkKL https://t…

RT @CCR_AACR: Phase I trial: RORγ agonist LYC-55716 in adults with relapsed/refractory metastatic cancer. https://t.co/frFxMaOkKL https://t…

RT @CCR_AACR: Phase I trial: RORγ agonist LYC-55716 in adults with relapsed/refractory metastatic cancer. https://t.co/frFxMaOkKL https://t…

Phase I trial: RORγ agonist LYC-55716 in adults with relapsed/refractory metastatic cancer. https://t.co/frFxMaOkKL https://t.co/IFSlCswqDX

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 8 additional X posts.